

ASX ANNOUNCEMENT | 18 August 2026

Cleansing Notice – Issue of Shares

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, lodges the following cleansing notice for the new ordinary shares:

Section 708A Cleansing Notice

The Company gives notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

- (a) it has today issued 152,549,425 fully paid ordinary shares (Shares) at an issue price \$0.012 (1.2 cents) per Share and 156,250,023 IBXO Listed Options expiring on 13 December 2027 (Options), in relation to the Placement announced by the Company on 25 June 2026;
- (b) the Shares and Options were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act
- (d) as at the date of this notice the Company has complied with:
 - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. sections 674 and 674A of the Corporations Act; and
- (e) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed pursuant to section 708A(6)(e).

Authorisation & Additional Information

This announcement was authorised by the Board of Imagion Biosystems Limited.

Join Imagion Biosystems' Investor Hub

Stay up to date on news and announcements or interact with our team through questions and comments via Investor Hub. Register at investor.imagionbiosystems.com.

About Imagion Biosystems

Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imagonbiosystems.com.

Executive Chairman Contact Details

Bob Proulx

investor@imagonbio.com

AU: +61 3 9692 7222

Media Enquiries & Investor Relations

Erich Boileau, Boileau & Co.

imagonbio@boileau.co

US : +1 (616) 786-4461